HENDERSON, Nev.--(BUSINESS WIRE)--United Health Products, Inc. (OTC: UEEC), (“UHP” or the “company”), manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose that is patented through Oct 2029 (US Patent 8,557,874 Oct 15,2013) for the healthcare and wound care sectors, today announced that is has recently received correspondence from the FDA regarding its current PMA class III submission for use in surgical applications . The company continues to coordinate and respond to FDA information requests in a timely manner.
Separately, UHP has developed a new dialysis patch to arrest post-dialysis bleeding. UHP is in discussions with major dialysis providers to initiate a pilot program to demonstrate the new product’s effectiveness.
About United Health Products
United Health Products develops technology, manufactures and markets patented hemostatic products for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all-natural product designed to control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.